今年以来，A股市场迎来16只新股上市，其中医疗器械企业占据四席，成为开年新股市场的亮点之一。 北京商报记者统计发现，年内上市的医疗器械企业包括科创板"新秀"北芯生命，以及北交所的海圣医 疗、爱得科技、爱舍伦，4只个股上市首日涨幅均超170%，展现出资本市场对医疗器械赛道的高度认 可。 股价亮眼的背后，是业绩基本面的支撑。作为以科创板第五套上市标准上市的企业，北芯生命预计去年 扭亏，另外3只北交所个股在去年的业绩均实现增长。目前，医疗器械企业上市"后备军"充足，其中人 工心脏领域的两家企业苏州同心医疗科技股份有限公司（以下简称"同心医疗"）和深圳核心医疗科技股 份有限公司（以下简称"核心医疗"）正共同冲刺"国产人工心脏第一股"。 上市首日表现亮眼 从市场表现看，北芯生命、海圣医疗、爱得科技、爱舍伦4只医疗器械新股可谓"开门红"。 交易行情显示，2月5日登陆科创板的北芯生命表现最为抢眼，上市首日收涨183.33%。盘中涨幅一度超 200%，全天成交金额达14.09亿元，总市值一度超过200亿元。作为医疗器械领域最新上市的新股，海 圣医疗于2月12日登陆北交所，上市首日大幅收涨172.86%。此外，爱得科技、爱舍伦 ...

Core Insights - The A-share market has welcomed 16 new listings since 2026, with four medical device companies standing out as a highlight of the new year [1] - The newly listed medical device companies have shown impressive first-day performance, with all four stocks rising over 170% on their debut [1][3] - The strong stock performance is supported by positive earnings forecasts, with all four companies expected to report growth in 2025 [1][5] Group 1: Market Performance - The four medical device stocks, including Beixin Life, Haiseng Medical, Aide Technology, and Aishalen, experienced significant first-day gains, with Beixin Life rising by 183.33% on its debut [3] - As of February 13, the stock prices for these companies ranged from 18.77 yuan to 39.48 yuan, with total market capitalizations between 22.17 billion and 164.6 billion yuan [3] - The medical device sector is currently in a high-growth cycle, attracting significant capital market attention [7] Group 2: Company Performance and Projections - Beixin Life, which focuses on cardiovascular disease diagnostic devices, is projected to turn a profit in 2025, with expected revenues between 520 million and 560 million yuan, representing a growth of 64.24% to 76.88% [6] - Haiseng Medical anticipates a revenue of 345 million yuan in 2025, a year-on-year increase of 13.68%, while Aide Technology expects approximately 302 million yuan, up 9.74% [6] - Aishalen forecasts revenues between 890 million and 940 million yuan, with a growth rate of 28.65% to 35.89% due to increased demand and expanded production capacity [6] Group 3: Industry Trends and Future Prospects - The medical device IPO trend continues, with several companies, including Guangdong Boma Medical Technology, in the pipeline for listing [8] - Companies like Core Medical and Tongxin Medical are also vying to become the first domestic artificial heart stock, despite not yet being profitable [9] - The medical device sector is shifting from "concept speculation" to "performance-driven" investments, emphasizing the importance of technological originality and profitability [9]

Company Overview - Beixin Life, a leading company in the domestic cardiovascular precision interventional diagnosis and treatment field, officially listed on the Sci-Tech Innovation Board on February 5 [2] - Yifeng Capital, an early investor in Beixin Life since 2020, views the listing as a milestone in its investment layout in the biopharmaceutical and high-tech medical device sectors [2] Investment Motivation - Beixin Life is the first domestic medical device company with a product portfolio that includes intravascular functional FFR and imaging IVUS [3] - The investment was driven by the desire to break the international monopoly in the cardiovascular interventional field, where domestic alternatives were still in the "deep water zone" for high-end active devices [3] - The company aims to create an "intelligent cardiovascular precision interventional diagnosis and treatment system," providing more precise decision support for clinical applications, aligning with Yifeng Capital's investment principle of addressing unmet clinical needs [3] Industry Trends - The investment trend in the biopharmaceutical and medical device sectors has shifted from "following" to "running alongside," with a focus on "source innovation" in high-end medical devices [4] - Early-stage investments, particularly in preclinical or clinical phase I, are becoming increasingly important as mature asset valuations are high, making early positioning beneficial for cost control [4] - China's innovation is transitioning from "Fast-follow" to "First-in-class," emphasizing the need for early intervention to capture disruptive technologies [4] IPO Policies and Exit Strategies - Ongoing reforms in capital markets, such as the Sci-Tech Innovation Board and Hong Kong's 18A, are facilitating the listing of unprofitable tech companies, which is significant for early-stage investment firms like Yifeng Capital [5] - The diversification of exit strategies, including IPOs, cross-border collaborations, mergers and acquisitions, and secondary share transfers, provides more flexible return options and reduces early investment risks [5] - Investors are increasingly rational in their valuation judgments, focusing on true clinical value and differentiated advantages rather than merely the number of product pipelines, which will drive the industry back to its innovative essence [5] Future Outlook - The investment landscape in hard technology and biomedicine is characterized by long cycles and high risks, prompting a call for a focus on "patient capital" and deep engagement in specific sectors [6] - The emphasis is on teams with a composite background of "scientists + industrialization," possessing both top scientific insight and understanding of product development and commercialization [6] - Yifeng Capital aims to act as a bridge between technology and industry, assisting companies in navigating the "last mile" from the laboratory to the market [6]

Group 1 - In January 2026, the A-share IPO market saw increased activity, with public funds becoming the dominant force in offline allocations due to their capital scale, research capabilities, and pricing advantages [1][4] - Public funds participated in the offline allocation of 5 new stocks, acquiring a total of 60.22 million shares worth 1.25 billion yuan, covering high-growth sectors such as semiconductors, wind power, medical devices, and automotive manufacturing [1][3] - Among the new stocks, semiconductor equipment and wind power materials were particularly favored, with Hengyun Chang and Zhenstone Co. receiving significant allocations, reflecting public funds' strong recognition of domestic semiconductor substitution and long-term optimism for high-end manufacturing in the renewable energy sector [1][2] Group 2 - In the medical innovation sector, Beixin Life, the first domestic company with a combination of vascular functional FFR and imaging IVUS products, attracted public fund allocations of 17.72 million shares worth 310 million yuan, highlighting the investment appeal in this field [2] - Public funds also participated in the offline allocations of Zhixin Co. (automotive welding components) and Shimon Co. (supply chain logistics solutions), with allocations of 102.33 million yuan and 71.22 million yuan respectively, further diversifying the coverage of public fund IPO activities [2] Group 3 - A total of 107 public fund institutions participated in the offline allocations in January, with a clear differentiation in allocation amounts; 31 institutions received less than 1 million yuan, while the top twenty institutions received no less than 10 million yuan, dominating the market [3] - Leading public funds such as E Fund, Southern Fund, and ICBC Credit Suisse Fund excelled in offline allocations, with E Fund acquiring 7.19 million shares worth 148 million yuan, leading among public institutions [4] - The active participation of public funds in IPOs is driven by the low-risk and quick-return characteristics of offline allocations, which have become an important stabilizer for fund returns, especially during market fluctuations [4][5] Group 4 - Public funds view IPO participation as a key strategy for accessing high-growth sectors, allowing them to lock in quality assets early and optimize their portfolio structure [5] - Looking ahead, the focus on hard technology, renewable energy, and medical innovation is expected to continue, with a stable supply of quality new stocks, although competition for allocations may intensify [5] - Top public funds with strong research capabilities and precise pricing will likely continue to dominate the IPO market, while smaller funds may need to seek differentiation through niche strategies and optimized pricing [5]

Core Viewpoint - The company is a national high-tech enterprise focused on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, aiming to transform solutions for cardiovascular care [7]. Company Overview - The company specializes in the research, development, production, and sales of innovative medical devices for cardiovascular disease diagnosis and treatment [7]. - It is the first domestic medical device company with a combination of vascular functional FFR and imaging IVUS products, filling a market gap and changing the reliance on imported products for coronary artery disease clinical diagnosis in China [12]. Financial Data - Projected revenue for 2024 is 3.17 billion yuan, up from 1.84 billion yuan in 2023 and 0.92 billion yuan in 2022 [8]. - The company reported a net loss of 0.54 billion yuan in 2024, an improvement from a loss of 1.55 billion yuan in 2023 and 3.00 billion yuan in 2022 [8]. - Cash flow from operating activities per share is expected to be 0.08 yuan in 2024, recovering from negative cash flows in previous years [8]. Industry Context - The cardiovascular disease market is expected to grow due to an aging population, with projections indicating that by 2030, the population aged 65 and above in China will reach 270 million, accounting for 19.6% of the total population [12]. - The increasing prevalence of obesity, hypertension, and diabetes is expected to drive the demand for cardiovascular disease diagnosis and treatment solutions [12]. SWOT Analysis Strengths - The company has a strong focus on independent research and technological innovation, which is crucial for developing solutions for cardiovascular diseases [12]. - It possesses a mature commercialization network recognized globally and regionally [12]. Opportunities - The trend of population aging and increasing regulatory focus on innovative medical devices present significant growth opportunities for the company [13]. Weaknesses - The company faces challenges due to the high difficulty and risk associated with developing Class III medical devices, which involve complex and lengthy processes [14]. - There is significant competition from established foreign manufacturers, and the company has relatively weak financial strength [14].

Group 1 - The capital market in Shenzhen has nurtured a high-quality group of listed companies, with 425 A-share listed companies and 159 overseas listed companies ranked among the top in comprehensive competitive strength [1] - As of August 15, 16 Shenzhen enterprises are in the process of applying for A-share IPOs, indicating a growing trend of technology innovation companies seeking public funding [2][5] - The IPO candidates include 6 companies aiming for the Shenzhen Stock Exchange, 3 for the Shanghai Stock Exchange's Sci-Tech Innovation Board, and 7 for the Beijing Stock Exchange, with 15 already in the inquiry stage [2] Group 2 - Among the IPO candidates, Huike Co., Ltd. stands out with total assets exceeding 100 billion yuan and projected revenue of 40.31 billion yuan in 2024, aiming to enhance its core competitiveness through increased R&D investment [2][4] - Hengyun Chang is noted for its rapid growth, with a compound annual growth rate (CAGR) of 84.91% in revenue and 156.72% in net profit from 2022 to 2024, focusing on semiconductor equipment manufacturing [4] - Many of the 16 companies have substantial orders and are looking to expand capacity or enter global markets, indicating a strong demand for their products [4] Group 3 - Shenzhen's listed companies have a significant focus on R&D, with over 50% of the 425 listed companies in the technology innovation sector, reflecting a trend towards high-quality production capabilities [5] - Companies like Kairui Zhi have invested heavily in R&D, achieving 615.34 million yuan in R&D expenses over three years and holding 247 patents, which strengthens their competitive edge [6] - The average gross margin for companies applying for the Sci-Tech Innovation Board and the Growth Enterprise Market is between 40% and 60%, showcasing their resilience in a changing market [6] Group 4 - The capital market is becoming more inclusive, allowing more "hard tech" companies to access funding, with new listing standards accommodating unprofitable but high-growth firms [7] - Companies like Beixin Life and Dapu Micro are examples of firms with rapid growth despite not being profitable, with Beixin Life's revenue projected to grow from 92.45 million yuan in 2022 to 317 million yuan in 2024 [7] - Dapu Micro focuses on enterprise-level SSD products and has seen its market scale grow rapidly, driven by the demand from artificial intelligence applications [7]

Group 1 - The core viewpoint is that Shenzhen's technology innovation enterprises are seizing development opportunities with 16 companies currently in line for A-share IPOs, which could inject strong momentum into the industry [3][4] - The capital market reforms are enhancing the attractiveness for high-tech and high-growth companies, facilitating financing channels for enterprises at different growth stages [4][10] - Among the 16 companies, 6 are targeting Shenzhen Stock Exchange IPOs, 3 are aiming for Shanghai Stock Exchange's Sci-Tech Innovation Board, and 7 are looking at Beijing Stock Exchange [4] Group 2 - Huike Co., a leading company in the semiconductor display panel industry, has total assets exceeding 100 billion yuan and aims to enhance its core competitiveness through IPO fundraising [4] - Hengrunchang is the fastest-growing company among the 16, with a compound annual growth rate (CAGR) of 84.91% in revenue and 156.72% in net profit from 2022 to 2024 [5] - Many companies are experiencing order surpluses and are looking to expand capacity or target global markets through capital market financing [6] Group 3 - Shenzhen's innovation is highlighted by the fact that over 50% of the 425 listed companies are from the Sci-Tech Innovation Board and Growth Enterprise Market, indicating a concentration of listing resources in new productive forces [7] - The companies in line for IPOs exhibit significant technological innovation, with substantial R&D investments and patent achievements forming competitive advantages [8][9] - Companies like Dapu Micro and Beixin Life have maintained high R&D investment ratios, with 36.15% and 65.5% of their cumulative revenue allocated to R&D over the past three years [9] Group 4 - The capital market is becoming more inclusive, allowing more "hard tech" companies to access funding, including those that are currently unprofitable [10] - Companies like Beixin Life and Dapu Micro are characterized by rapid growth despite not being profitable, with Beixin Life's revenue projected to grow from 92.45 million yuan in 2022 to 317 million yuan in 2024 [11] - Shenzhen is actively cultivating the "20+8" industrial clusters, with emerging companies in sectors like semiconductors, artificial intelligence, humanoid robots, and biomedicine rapidly growing [11]

Core Insights - July 18 marked a significant day for the capital market with multiple key approvals from the China Securities Regulatory Commission (CSRC) [1] - The approvals indicate an acceleration in the review process for quality mergers and acquisitions, as well as a more inclusive approach for IPOs on the Sci-Tech Innovation Board [1][7] Group 1: Mergers and Acquisitions - The CSRC approved China Shipbuilding Industry Company’s absorption merger with China Shipbuilding Heavy Industry Company, marking a significant step in the integration of two major listed platforms under the China Shipbuilding Group [2] - The merger is the first to complete the Shanghai Stock Exchange review and CSRC registration under the new restructuring regulations, setting a precedent for future mergers [2] - ChipLink Integrated Circuit Manufacturing Co. received approval for a significant asset restructuring deal, involving the acquisition of 72.33% of ChipLink Yuezhou Integrated Circuit Manufacturing for a total transaction value of 5.897 billion yuan, despite both companies currently being unprofitable [2][3] Group 2: Initial Public Offerings (IPOs) - Wuhan Heyuan Biotechnology Co. became the first company to receive IPO registration approval under the newly restarted fifth set of standards on the Sci-Tech Innovation Board [4] - Heyuan Biotechnology plans to raise 2.4 billion yuan for the construction of a recombinant human albumin production base, new drug development, and to supplement working capital [5] - Shenzhen Beixin Life Technology Co. also passed the listing review under the new standards, focusing on high-performance innovative medical devices for cardiovascular interventions [5] - Yushu Technology has initiated the IPO counseling process, with plans for a comprehensive evaluation of its listing conditions by October 2025 [5][6]